the weizmann institute of sciencecnd.kddf.org › download › 04_2ndkddfgcnd_yeda.pdf ·...
TRANSCRIPT
1
Discovering Basic ScienceThe Weizmann Institute of Science
2
THE WEIZMANN INSTITUTE OF SCIENCE FOCUSED ON RESEARCH
260Professors
Heading research groups
400Administrative
staff
850Scientists
Ph.D.’s, engineers & technicians
1000Students
M.Sc. and Ph.D. only
3
THE WEIZMANN INSTITUTE OF SCIENCE FIVE FACULTIES
Mathematics
Computer Science
Chemistry Biology
Physics Biochemistry
The focus of scientists is
excellence inBasic Science
4
THE WEIZMANN INSTITUTE OF SCIENCELEIDEN RANKING
5
YEDA INDUSTRY IMPACT
80 companiesEstablished around Yeda’s
technologies
200 productsWith “Weizmann-Inside” technology
on the market
2070 patent families Filed since 1971
$22 billionAnnual WIS product sales
Yeda is the commercialization company with the highest income per researcher worldwide
Over 160 patent disclosures weresubmitted by WIS scientistsbetween 2013-2014
6
LICENSING INCOME SURVEY 2012 TOP 10 UNIVERSITIES *
Institution Licensing Income ($M)
1City of Hope National Medical Center. & Beckman Research
224
2 NYU 184
3 Columbia Univ. 161
4 Sloan Kettering Inst. For Cancer Res. 143
5Massachusetts Institute ofTechnology (MIT)
137
6 Princeton University 130
7 Northwestern University 122
8 Univ. California System 102
9The General Hospital dbaMassachusetts General Hos.
99
10 University of Washington 77
* Source: AUTM Licensing Survey 2012
7
$4,027M
$2,434M
COPAXONE
Rebif
COPAXONE and Rebif are two blockbuster treatments for multiple sclerosis developed at the Weizmann institute
SUCCESS STORIES MULTIPLE SCLEROSIS TREATMENT
$2,912MAVONEX
Other
Weizmann
8
FROM A SINGLE PATENT TO THREE DRUGS
$1,081 MILLIONErbitux® Merck and Eli Lillymetastatic colorectal cancer
$359 MILLIONVectibix® AMGENColorectal cancer
$500 M (EST 2016)Portrazza® Eli LillyLung cancer
Prof. Sela and colleagues discovered that EGFR-inhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy
The three EGFR blockers are saving the lives of hundreds of thousands of cancer patients all over the world
EGFR blockers
9
AbbVie’s leading product, responsible for up to 57% of its overall sales
Worldwide sales: $12.54 billion in 2014
HUMIRA® was the first fully human monoclonal antibody drug approved by the FDA
It was ranked the best selling drug worldwide in 2013
SUCCESS STORIES HUMIRA
10
TOOKAD®Targeted photodynamic
therapy
A result of collaboration between the Weizmann Institute and Steba biotech
Recently approved therapy for prostate cancer in Mexico and in Israel
European Phase III clinical trial is currently under evaluation by the EMA
TOOKAD® Soluble VTP is a day-case procedure lasting approximately 90 minutes. This new minimally invasive technology offers a good alternative to patients diagnosed with early-stage prostate cancer
Prof. Avigdor Scherz and Prof. Yoram Salomon
11
WORLD LEADING SCIENTISTS
PROF. ADA YONATH
• The pioneer of ribosome crystallography
• Nobel Laureate in Chemistry, 2009
• The first Israeli woman to win the NobelPrize out of ten Israeli Nobel laureates
PROF. ZELIG ESHHAR
Developed the first CAR T-cells
(novel strategy for cancer treatment with promising results and multi-billion dollar market )
12
TURING AWARD LAUREATES
PROF. ADI SHAMIR
A world leading cryptographer
co-inventor of the RSA algorithm for secure data transmission
PROF. AMIR PNUELI
Received the Turing Award in 1996 for seminal work introducing temporal logic into computing science and for outstanding contributions to program and systems verification
PROF. SHAFI GOLDWASSER
Her work on laid the rigorous foundations for modern cryptography and pioneered several themes which are today considered basic to the field
13
INTERDISCIPLINARY INNOVATION
Dr. Eran Elinav
A new start-up based on
Weizmann science
Prof. Eran Segal
Host-microbiome interactions and their effects on health
and disease
Computer Science and Applied Mathematics
Personalized nutrition based on gut microbiome
14
Yeda has a diverseportfolio whichcovers a broadspectrum of thepharmaceutical andbiotech industry
THE CURRENT TECHNOLOGY PIPELINE
Drug Targets Small molecules Antibodies
Diagnostics Research toolsMedical Device
15
TO MAKE THE NEXT SCIENTIFIC BREAKTHROUGH
PARTNER WITH US